When: Confirmed close >$134.71 with MACD turning positive

Then: Add on upside confirmation

When: Price at $128

Then: Scale in via tranche

HOLD - Do not initiate or add at current levels ($132). Wait for price confirmation at $124-$128, using tranches with stop at $121.

• Technical deterioration: Price below 10 EMA, below 50 SMA, MACD negative below signal line and zero, RSI at 43.9, lower-high pattern since June peak at $147.21
• Invalidation level: Clean close above $134.71 with MACD crossing back to positive required before bullish stance
• Valuation trap: Forward EPS $12.89 requires 84% jump from 2025 actual EPS of $6.99; Q1 $3.06 and Q2 $3.15 show zero sequential growth—cannot annualize single quarters
• Macro risk: 30-year Treasury at highest since 2004, 10-year at 5%, loan book up 14.6% over 18 months represents late-cycle lending behavior
• Capital return concern: ROE of 8.5% versus JPMorgan's ~17% suggests management returns capital because it cannot earn cost of equity; buybacks are mechanical EPS expansion, not organic compounding
• Asymmetric setup challenge: Target of $155-$165 requires both EPS validation AND multiple expansion from 10.25x to ~12.5x—a low-probability joint event
• Current ATR is 2.7% with 38% quarter-over-quarter EPS volatility
• Recommended entry: $124-$128 at or below 200 SMA with confirmation of price action; tight stop at $121
• Alternative entry: $148 on breakout with momentum-following strategy

→ vs aggressive: Technical 'healthy consolidation' claim ignores price below 10 EMA, 50 SMA, and Bollinger midline simultaneously with negative MACD—dismissing every moving average cluster as noise is not analytical rigor

→ vs aggressive: Valuation PEG of 0.6 is a trap when the growth number is one quarter of extrapolated hope—forward EPS assumes 84% jump in single year for $2.9T bank

→ vs aggressive: Macro NII tailwind ignores credit-cycle implications: 14.6% loan growth into 5% 10-year Treasury is exactly what banks did in 2006-2007; Polymarket 10% recession odds + negative earnings-revision breadth + bond market stress = three signals being ignored

→ vs aggressive: Capital return framing is backwards—$23.6B annual return with 8.5% ROE is a confession of inability to earn cost of equity, not a celebration; buybacks are first thing pulled if credit event hits

→ vs aggressive: Asymmetric risk/reward framing ignores that stock ran from $93 to $147—much of easy multiple expansion is behind us; 'risking $8 to make $23-$33' assumes both upside scenarios materialize simultaneously

MAINTAIN position; ADD on staged tranches at $129.61 (1st), $124.28 (2nd), and $134.71 breakout with positive MACD (3rd); STOP tightened to $121

• Current price $132 is too elevated to add; technical deterioration (below 10 EMA, 50 SMA, negative MACD, RSI 43.9) is meaningful signal not noise
• Forward P/E of 10.25 and PEG of 0.6 present attractive valuation that supports staying long but not adding aggressively
• Target price $155 to $165 (from aggressive analyst) requires both EPS validation AND multiple expansion simultaneously after 2.6x three-year run
• ROE of 8.5% versus JPM 17% explains the valuation discount; even modest ROE expansion to 11-12% triggers mechanical multiple expansion
• Q1 $3.06 and Q2 $3.15 EPS represent ~3% sequential growth off seasonally weak quarters, supporting full-year $12.80 to $13.00
• Downside risk to 200 SMA at $124.28 represents ~6% drawdown; ATR is 2.7% making 8% downside ($121 stop) appropriate
• Capital return commitment is strategic priority, not routine capital decision; full abandonment unlikely
• Tranche sizing at one-third each preserves dry powder if only partial levels trigger

→ vs aggressive: Target of $155 to $165 requires simultaneous EPS validation AND multiple expansion after 2.6x run; the easy multiple expansion is largely behind us

→ vs aggressive: Technical setup is not noise to be ignored; RSI at 43.9, negative MACD, and lower highs since June ($147.21) indicate market actively questioning $12.89 forward EPS

→ vs conservative: ROE gap of 8.5% vs JPM 17% is already priced in at 10.25x; if simplification delivers 11-12% ROE, multiple expansion follows mechanically - market not pricing full ROE normalization

→ vs conservative: Q1 $3.06 plus Q2 $3.15 shows ~3% sequential growth off weak quarters; extrapolating to $12.80-$13.00 full year is reasonable, not fantasy

→ vs conservative: 'Wait for perfect confirmation' has its own cost; buying on confirmed breakout at $134.71 with positive MACD is high-quality momentum entry, not missed opportunity